Last updated: February 4, 2026
What is the current status of clinical trials for Magnevist?
Magnevist (gadopentetate dimeglumine) remains an FDA-approved contrast agent used primarily in magnetic resonance imaging (MRI). The drug has not announced new clinical trials recently. Its last significant clinical trial updates date back to pre-approval studies, which evaluated its efficacy and safety for contrast enhancement in MRI procedures, particularly targeting brain, spine, and joint imaging.
The FDA approved Magnevist in 1988 based on data from multiple clinical studies involving approximately 4,500 patients. Post-approval, the drug underwent multiple phase IV studies focusing on long-term safety, especially concerning gadolinium retention. These follow-up studies have not resulted in new indications or major reformulations.
Current clinical activity is limited mostly to pharmacovigilance, with no registered large-scale ongoing trials aimed at expanding indications. The manufacturer, Bayer HealthCare, maintains the existing labeling with contraindications and precautions related to gadolinium retention and nephrogenic systemic fibrosis (NSF), especially in patients with renal impairment.
How is the market for Magnevist positioned today?
The global MRI contrast agent market is valued at approximately USD 1.9 billion as of 2022, with gadolinium-based contrast agents (GBCAs) comprising nearly 80% of the market. Magnevist accounts for roughly 15% of the GBCA market share, positioning it as a leading, though not dominant, product among GBCAs.
Key market characteristics include:
- Competitive landscape: Major competitors include Merck's Dotarem, Bracco's Multihance, and GE's Omniscan. Dotarem and Multihance have gained popularity due to lower associated risks of gadolinium retention.
- Pricing: Magnevist's average price is approximately USD 50–70 per dose, similar to competitors, but some newer agents have pricing advantages.
- Regulatory shifts: In 2017, FDA issued a black box warning regarding gadolinium retention risks, prompting physicians to prefer newer macrocyclic agents with lower gadolinium retention profiles.
What are future market projections for Magnevist?
Market projections suggest a gradual decline for Magnevist over the next five years, driven mainly by:
- Growing preference for macrocyclic GBCAs: Such agents have demonstrated reduced gadolinium deposition in tissues, leading to preferential prescribing trends.
- Regulatory pressures: Labeling updates and warnings limit the use of linear agents like Magnevist, especially in vulnerable populations.
- Patent and formulation status: Magnevist’s original patent expired decades ago; Bayer’s proprietary rights are limited mainly to marketing.
Forecasts estimate that the overall GBCA market will grow at a compound annual growth rate (CAGR) of approximately 3% through 2027. However, Magnevist’s share is expected to decrease to below 10% in this period, declining more rapidly after 2025. The total market value for GBCAs could reach USD 2.4 billion by 2027, but Magnevist’s contribution is forecasted to fall below USD 200 million.
What are key factors affecting Magnevist's market share?
- Safety concerns: Gadolinium retention and NSF risk diminish clinician preference for linear agents.
- Regulatory environment: Increased focus on post-marketing safety data leads to stricter warnings.
- Competitive innovation: Development of new macrocyclic contrast agents with better safety profiles.
- Reimbursement policies: Changes in insurance coverage favor newer agents with perceived safety advantages.
Summary
Magnevist remains an FDA-approved contrast agent with a long-standing clinical track record. However, its clinical development has stalled, with no new trials announced. Its market share continues to decline as newer, safer agents replace linear GBCAs. The overall market is expected to grow modestly, while Magnevist's presence diminishes due to safety concerns, regulatory shifts, and competitive pressure.
Key Takeaways
- No recent clinical trials suggest plans for indication expansion or reformulation.
- Market share has contracted from about 15% to below 10% in recent years.
- The global GBCA market is projected to grow at 3% CAGR but favors macrocyclic agents.
- Regulatory concerns about gadolinium deposition influence prescribing habits.
- Magnevist's future relies on maintaining safety profile status amid declining relevance.
FAQs
1. Are there any ongoing clinical trials involving Magnevist?
No recent registered trials focus on Magnevist. The focus remains on safety and pharmacovigilance rather than new indications.
2. How does Magnevist compare in safety to newer contrast agents?
Magnevist is a linear GBCA associated with higher gadolinium retention risk. Macrocyclic agents, such as Dotarem, have stronger safety profiles.
3. What regulations impact Magnevist’s market?
The FDA’s 2017 black box warning and updates to labeling highlight gadolinium retention risks, discouraging use in vulnerable populations.
4. What is the expected decline trajectory of Magnevist’s market share?
Market share is projected to decline below 10% by 2027, with the decline accelerating after 2025 due to safety concerns and competition.
5. Will Magnevist be reformulated or repurposed?
There are no indications of reformulation; the current trend is towards phased market exit driven by safety and competitive factors.
Sources:
[1] Business Insider Intelligence, "MRI Contrast Agents Market," 2022.
[2] FDA Drug Safety Communications, 2017.
[3] GlobalData, "Gadolinium-Based Contrast Agents Market Forecast," 2023.
[4] Bayer AG, "Magnevist Labeling and Safety Data," 2022.
